Amendment to Schedule 13D Filing for NextCure, Inc.

This filing is an Amendment No. 2 to the Schedule 13D originally filed on May 17, 2019, by Sofinnova Venture Partners IX, L.P. ("SVP IX"), Sofinnova Management IX, L.L.C. ("SM IX"), and Dr. James I. Healy ("Healy"). The amendment is filed to update the aggregate percentage of Common Stock beneficially owned by the Reporting Persons. This update is necessitated by the Issuer's (NextCure, Inc.) additional sales of Common Stock, which have caused dilution and a decrease of one percent (1%) or more in the Reporting Persons' aggregate ownership percentage. The Reporting Persons hold their securities for investment purposes and may adjust their holdings based on various factors. The filing details the principal business of the Reporting Persons, their citizenship, and addresses. It also outlines the sources of funds for their past purchases of the Issuer's securities, primarily working capital. The Reporting Persons have not effected any transactions in the securities of the Issuer during the past 60 days, except as otherwise noted. The filing also references existing agreements, including an Investors' Rights Agreement and Lock-Up Agreements.